Page 179 - Comprehensive treatment of patients with glucocorticoid-dependent severe asthma

References
1. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985–993
2. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184–90.
3. Rabe KF, Parameswaran N, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475-85.
4. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo- controlled study. Am J Respir Crit Care Med. 2011;184(10):1125-32.
5. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade LM, Shah PL, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181(2):116-24.
6. Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO workshop report. 2018. Available from: https://ginasthma.org/2018-gina-report-global-strategy- for-asthma-management-and-prevention/ (last accessed december 2018)
7. Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol. 2006;533(1-3):2-14.
8. Sullivan PW. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141:110-6.
9. Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in literature. Eur Respir J. 2018;52(4). pii: 1800703. doi: 10.1183/13993003.00703-2018. Print 2018 Oct.
10. Manson SC. The cumulative burden of oral corticosteroids side effects and the economic implications of steroid use. Respir med 2009;103:975-994.
11. O’Neill S, Sweeney J, Patterson CC, Menzies-Gow A, Niven R, Mansur AH, Bucknall C, Chaudhuri R, Thomson NC, Brightling CE, O’Neill C, Heaney LG. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015;70:376-378.
12. Foster JM, McDonald VM, Guo M, Reddel HK. “I have lost in every facet of my life”: the hidden burden of severe asthma. Eur Respir J. 2017,50(3) 1700765; DOI: 10.1183/13993003.00765-2017
13. Randhawa I, Klaustermeyer WB. Oral corticosteroid-dependent asthma: a 30-year review. Ann Allergy Asthma Immunol. 2007;99(4):291-302.
14. Boardley J.E CRA, Harvey A.M. Preliminary observations on the effects of adrenocorticotropic hormone in allergic diseases. Bull. Johns Hopkings Hosp. 1949;85:396-410.
15. Phear D, Ball K, Page F. Prolonged treatment with steroids in severe chronic asthma. Lancet. 1960;1(7116):139-41.
16. Pavord ID, Korn S, Howarth P, Bleecker Er, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380(9842):651-9.
17. Konstantinou GN. Pragmatic trials: how to adjust for the ‘Hawthorne effect’? Thorax. 2012;67(6):562; author reply
18. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189–1197.
19. https://ginasthma.org/wp-content/uploads/2018/11/GINA-SA-FINAL-wms.pdf (last accessed December 2018)
Nederlandse samenvatting
177
11